Provided by Tiger Fintech (Singapore) Pte. Ltd.

MiNK Therapeutics, Inc.

7.59
-0.0105-0.14%
Volume:4.27K
Turnover:32.49K
Market Cap:30.10M
PE:-2.66
High:7.95
Open:7.56
Low:7.24
Close:7.60
Loading ...

Mink Therapeutics Inc - to Effect 1-for-10 Reverse Stock Split

THOMSON REUTERS
·
22 Jan

Dr Boreham’s Crucible: This cancer-tackling, cell-therapy player might just have a fighting chance

Stockheads
·
07 Jan

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

GlobeNewswire
·
18 Dec 2024

Health Check: No sign of frayed nerves as Orthocell girds for US approval

Stockheads
·
02 Dec 2024

Q3 2024 Mink Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
15 Nov 2024

MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com
·
15 Nov 2024

MiNK Therapeutics Reports Q3 Growth and Strategic Advances

TIPRANKS
·
15 Nov 2024

Mink Therapeutics Inc: Qtrly Loss per Share $0.05

THOMSON REUTERS
·
14 Nov 2024

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

GlobeNewswire
·
14 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
13 Nov 2024

Mink Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
12 Nov 2024

BRIEF-Mink Therapeutics To Provide Corporate Update And Third Quarter 2024 Financial Report

Reuters
·
11 Nov 2024

Mink Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

THOMSON REUTERS
·
11 Nov 2024

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

GlobeNewswire
·
11 Nov 2024

MiNK Therapeutics presents data on iNKT cell therapy programs

TIPRANKS
·
07 Nov 2024

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

GlobeNewswire
·
07 Nov 2024